Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 19;18(2):sfae415.
doi: 10.1093/ckj/sfae415. eCollection 2025 Feb.

Effects of spironolactone on intradialytic hypertension: a multicentre, double-blind, randomized, crossover study

Thanawat Vongchaiudomchoke  1 , Phimpraphan Khumngeon  1 , Nuttaya Wachiraphansakul  1 , Wipada Songwattana  2 , Jomchai Luechoowong  2 , Surapon Nochaiwong  3   4 , Chidchanok Ruengorn  3   4 , Kajohnsak Noppakun  2   4
Affiliations

Effects of spironolactone on intradialytic hypertension: a multicentre, double-blind, randomized, crossover study

Thanawat Vongchaiudomchoke et al. Clin Kidney J. .

Abstract

Background: Intradialytic hypertension (IDH) is associated with an increase in hospitalization and mortality. Several studies have shown that spironolactone reduces pre-dialysis blood pressure. However, none evaluated its effect on IDH. This study aims to evaluate the effects of spironolactone on IDH.

Methods: A 24-week, two-treatment, four-period, multicentre, double-blind, randomized, crossover study was conducted in stable maintenance haemodialysis (HD) patients who experienced IDH in >30% of their sessions during the past 3 months. Each participant was randomly assigned to one of four treatment sequences. In each intervention period, patients received a single dose of 50 mg spironolactone or a placebo 30 minutes before undergoing HD for 4 weeks according to their preassigned sequence, separated by a 2-week washout period. The primary outcome was an incidence of IDH.

Results: A total of 49 eligible patients were recruited with a total of 1211 dialysis sessions. The mean age was 54 ± 14 years and the mean systolic and diastolic blood pressures (SBP and DBP) were 145 ± 15 and 75 ± 10 mmHg, respectively. All patients had hypertension. The average number of antihypertensive drugs was 3.5 ± 1.4. Spironolactone reduced the incidence of IDH compared with placebo (57% versus 69%, P for treatment effect < .001). Patients receiving spironolactone had lower peak intradialytic SBP (161 ± 14 versus 165 ± 13 mmHg, P = .003), mean intradialytic SBP (149 ± 13 versus 152 ± 12 mmHg, P = .01) and post-dialysis SBP (152 ± 15 versus 157 ± 14 mmHg, P < .001) than placebo.

Conclusion: In maintenance HD patients who had frequent IDH, a pre-dialysis 50-mg spironolactone administration significantly decreased the incidence of IDH.

Trial registration: Thai Clinical Trial Registry, reference number TCTR20200604013.

Keywords: blood pressure + renal dialysis; chronic; haemodialysis; hypertension + renal dialysis; kidney failure; spironolactone.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Graphical Abstract
Graphical Abstract
Figure 1:
Figure 1:
Eligibility, enrolment and randomization.
Figure 2:
Figure 2:
Prespecified subgroup analyses for the incidence of IDH.
Figure 3:
Figure 3:
Serum potassium after completing each study period.
See this image and copyright information in PMC

References

    1. Iatridi F, Theodorakopoulou MP, Papagianni A et al. Intradialytic hypertension: epidemiology and pathophysiology of a silent killer. Hypertens Res 2022;45:1713–25. 10.1038/s41440-022-01001-3 - DOI - PubMed
    1. Inrig JK, Patel UD, Toto RD et al. Association of blood pressure increases during hemodialysis with 2-year mortality in incident hemodialysis patients: a secondary analysis of the Dialysis Morbidity and Mortality Wave 2 Study. Am J Kidney Dis 2009;54:881–90. 10.1053/j.ajkd.2009.05.012 - DOI - PMC - PubMed
    1. Inrig JK, Oddone EZ, Hasselblad V et al. Association of intradialytic blood pressure changes with hospitalization and mortality rates in prevalent ESRD patients. Kidney Int 2007;71:454–61. 10.1038/sj.ki.5002077 - DOI - PMC - PubMed
    1. Yang C-Y, Yang W-C, Lin Y-P. Postdialysis blood pressure rise predicts long-term outcomes in chronic hemodialysis patients: a four-year prospective observational cohort study. BMC Nephrol 2012;13:12. 10.1186/1471-2369-13-12 - DOI - PMC - PubMed
    1. Inrig JK. Intradialytic hypertension: a less-recognized cardiovascular complication of hemodialysis. Am J Kidney Dis 2010;55:580–9. 10.1053/j.ajkd.2009.08.013 - DOI - PMC - PubMed

LinkOut - more resources